Oregon is currently home to 1204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
NCT05589896
Recruiting
The goal of this clinical trial is to determine the safety and feasibility of allogeneic transplantation with bone marrow from a deceased donor in patients with acute and chronic leukemias, myelodysplastic syndrome, and certain lymphomas. Patients will either receive myeloablative conditioning or reduced intensity conditioning regimen prior to the transplant. Patients will be followed for 56 days for safety endpoints and remain in follow-up for one year.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/23/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia, CLL (Chronic Lymphocytic Leukemia), Chronic Myeloid Leukemia (CML), MDS (Myelodysplastic Syndrome), Non-Hodgkin Lymphomas, Hodgkins Lymphoma, Cutaneous T Cell Lymphomas (CTCL)
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Oregon Oncology Specialists, Salem, Oregon
Conditions: Breast Cancer
Register for Updates
Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors
NCT05479812
Recruiting
A first-in-human, Phase I, open-label, multicenter study of WTX-124 administered as monotherapy and in combination with pembrolizumab to patients with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Providence Cancer Institute Franz Clinic, Portland, Oregon
Conditions: Metastatic Solid Tumor, Advanced Solid Tumor
Register for Updates
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
NCT04262206
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
ALL
Ages:
75 years and above
Trial Updated:
06/23/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Register for Updates
Molecular Genetics Studies of Cancer Patients and Their Relatives
NCT04185935
Recruiting
This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.
Gender:
ALL
Ages:
All
Trial Updated:
06/23/2025
Locations: Saint Charles Health System, Bend, Oregon
Conditions: Malignant Neoplasm
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Oregon Health & Science University Hospital, Portland, Oregon
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
NCT06500273
Recruiting
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal residual disease (MRD) as detected by the Foresight CLARITY™ Investigational Use Only (IUO) MRD test, powered by PhasED-Seq™. The purpose of the trial is to assess the efficacy and safety of consolidation with cemacabtagene ansegedleucel (cema-cel), an allogeneic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Oncology Associates of Oregon, Eugene, Oregon
Conditions: Large B-cell Lymphoma
Register for Updates
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
NCT06395753
Recruiting
The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Oregon Urology Institut, Springfield, Oregon
Conditions: Prostate Cancer
Register for Updates
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821
Recruiting
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene, Oregon
Conditions: CLL
Register for Updates
Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome
NCT06066502
Recruiting
The goal of this interventional study is to compare standard mechanical ventilation to a lung-stress oriented ventilation strategy in patients with Acute Respiratory Distress Syndrome (ARDS). Participants will be ventilated according to one of two different strategies. The main question the study hopes to answer is whether the personalized ventilation strategy helps improve survival.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Acute Respiratory Distress Syndrome, Respiratory Failure
Register for Updates
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444
Recruiting
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Chronic migraine is defined as having at least 15 days of headache a month with at least 8 of those days being migraine headache day... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Providence Neurological Specialties West, Portland, Oregon
Conditions: Chronic Migraine
Register for Updates
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT05812027
Recruiting
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. The purpose of this screening study is to collect samples to conduct HLA genotyping, HLA Loss of Heterozygosity (LOH) assessment, and expression of Tumor-associated Antigens (TAA) testing. These results will be used to determine if participan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2025
Locations: Providence Cancer Institute Franz Clinic, Portland, Oregon
Conditions: Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
Register for Updates